Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) closed at $38.45 in the last session, down -0.18% from day before closing price of $38.52. In other words, the price has decreased by -$0.18 from its previous closing price. On the day, 0.6 million shares were traded. RYTM stock price reached its highest trading level at $39.1 during the session, while it also had its lowest trading level at $38.25.
Ratios:
We take a closer look at RYTM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.43 and its Current Ratio is at 5.58. In the meantime, Its Debt-to-Equity ratio is 0.63 whereas as Long-Term Debt/Eq ratio is at 0.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $55 from $29 previously.
On August 01, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $22 to $27.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when German Christopher Paul sold 368 shares for $41.76 per share. The transaction valued at 15,368 led to the insider holds 795 shares of the business.
Shulman Joseph sold 18,235 shares of RYTM for $735,600 on Mar 21 ’24. The Chief Technical Officer now owns 30 shares after completing the transaction at $40.34 per share. On Mar 20 ’24, another insider, Lee Jennifer Kayden, who serves as the EVP, Head of North America of the company, sold 18,235 shares for $38.77 each. As a result, the insider received 707,005 and left with 6,852 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 2312402176 and an Enterprise Value of 2143959040. For the stock, the TTM Price-to-Sale (P/S) ratio is 29.86 while its Price-to-Book (P/B) ratio in mrq is 13.46. Its current Enterprise Value per Revenue stands at 27.69 whereas that against EBITDA is -11.741.
Stock Price History:
The Beta on a monthly basis for RYTM is 1.94, which has changed by 0.8978282 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, RYTM has reached a high of $52.57, while it has fallen to a 52-week low of $15.50. The 50-Day Moving Average of the stock is -11.36%, while the 200-Day Moving Average is calculated to be 16.93%.
Shares Statistics:
According to the various share statistics, RYTM traded on average about 608.74K shares per day over the past 3-months and 514200 shares per day over the past 10 days. A total of 59.43M shares are outstanding, with a floating share count of 53.27M. Insiders hold about 11.43% of the company’s shares, while institutions hold 102.57% stake in the company. Shares short for RYTM as of 1711584000 were 9735262 with a Short Ratio of 15.99, compared to 1709164800 on 9004376. Therefore, it implies a Short% of Shares Outstanding of 9735262 and a Short% of Float of 25.990000000000002.
Earnings Estimates
A detailed examination of Rhythm Pharmaceuticals Inc. (RYTM) is currently in progress, with 9 analysts providing valuable insights into its market dynamics.On average, analysts expect EPS of -$2.16 for the current quarter, with a high estimate of -$0.59 and a low estimate of -$2.41, while EPS last year was -$0.92. The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.59 and low estimates of -$0.8.
Analysts are recommending an EPS of between -$2.19 and -$4.95 for the fiscal current year, implying an average EPS of -$4.14. EPS for the following year is -$2.04, with 9 analysts recommending between -$0.79 and -$3.84.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $27.02M. It ranges from a high estimate of $28M to a low estimate of $25.8M. As of the current estimate, Rhythm Pharmaceuticals Inc.’s year-ago sales were $11.47M, an estimated increase of 135.60% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $31.57M, an increase of 64.20% less than the figure of $135.60% in the same quarter last year. There is a high estimate of $33.9M for the next quarter, whereas the lowest estimate is $29.6M.
A total of 9 analysts have provided revenue estimates for RYTM’s current fiscal year. The highest revenue estimate was $141M, while the lowest revenue estimate was $115.61M, resulting in an average revenue estimate of $133.03M. In the same quarter a year ago, actual revenue was $77.43M, up 71.80% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $207.54M in the next fiscal year. The high estimate is $298.46M and the low estimate is $164.72M. The average revenue growth estimate for next year is up 56.00% from the average revenue estimate for this year.
